您的位置：首页 > 产品中心 > eIF4E/eIF4G Interaction Inhibitor II, 4E1RCat-Calbiochem
eIF4E/eIF4G Interaction Inhibitor II, 4E1RCat-Calbiochem
| 产品编号： | 4156717 |
| 规格： | The eIF4E/eIF4G Interaction Inhibitor II, 4E1RCat controls the biological activity of eIF4E/eIF4G interaction. This small molecule/inhibitor is primarily used for Phosphorylation & Dephosphorylation applications. |
| 包装规格： | 10 MG |
| 产品类别： | 进口试剂 |
| 品牌： | Sigma-Aldrich |
| 优惠价： | 立即咨询 |
产品别名
eIF4E/eIF4G Interaction Inhibitor II, 4E1RCat-Calbiochem
4-((3 E)-3-((5-(4-Nitrophenyl)furan-2-yl)methylidene)-2-oxo-5-phenyl-2,3-dihydro-1H-pyrrol-1-yl)benzoic acid, eIF4F Inhibitor II
基本信息
| Empirical Formula【经验(实验)分子式】 | C28H18N2O6 |
| Molecular weight | 478.45 |
| General description【一般描述】 | A cell-permeable oxopyrrolyl benzoate compound that blocks the assembly of eukaryotic translation initiation factor (eIF) 4F complex (eIF4F) as well as disrupts preformed eIF4F by competing against eIF4G for eIF4E binding. Specifically blocks cap-dependent, but not cap-independent, protein translations in cell-free translation assays and inhibits protein, but not DNA or RNA, synthesis in MDA-MB-231 and HeLa cultures (50 µM) in a reversible manner. Although not effective when administered alone (15 mg/kg, i.p. daily for 5 days), 4E1RCat is shown to significantly prolong Pten+/-Eµ-myc and Tsc+/-Eµ-myc, but not Eµ-myc, tumor remission time when combined with Doxorubicin (Cat. No. 324380) treatment (10 mg/kg, i.p. once on day 2) in mice in vivo. Unlike 4EGI-1 (Cat. No. 324517), 4E1RCat also blocks eIF4E and 4E-BP1 interaction. A cell-permeable oxopyrrolyl benzoate compound that blocks the assembly of eukaryotic translation initiation factor (eIF) 4F complex (eIF4F) as well as disrupts preformed eIF4F by competing against eIF4G for eIF4E binding. Specifically blocks cap-dependent, but not cap-independent, protein translations in cell-free translation assays and inhibits protein, but not DNA or RNA, synthesis in MDA-MB-231 and HeLa cultures (50 µM) in a reversible manner. Although not effective when administered alone (15 mg/kg, i.p. daily for 5 days), 4E1RCat is shown to significantly prolong Pten+/-Eµ-myc and Tsc+/-Eµ-myc, but not Eµ-myc, tumor remission time when combined with Doxorubicin (Cat. No. 324380) treatment (10 mg/kg, i.p. once on day 2) in mice in vivo. Unlike 4EGI-1 (Cat. No. 324517), 4E1RCat also blocks eIF4E and 4E-BP1 interaction. |
| Warning【警告】 | Toxicity: Standard Handling (A) |
| Reconstitution【重悬】 | Very fluffy material, not recommended for subdividing solid material by hand-weighing. Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C. |
| Other Notes【其他说明】 | Cencic, R., et al. 2011. Proc. Natl. Acad. Sci. USA108, 1046. |
| Legal Information【法律信息】 | CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany |
产品性质
| Quality Level【质量水平】 | 100 |
| Assay【测定】 | ≥97% (HPLC) |
| form【形式】 | solid |
| manufacturer/tradename | Calbiochem® |
| storage condition【储存条件】 | OK to freeze protect from light |
| color【颜色】 | dark brown |
| solubility【溶解性】 | DMSO: 50 mg/mL |
| shipped in【运输】 | ambient |
| storage temp.【储存温度】 | 2-8℃ |
| packaging【包装】 | 10 mg in Glass bottle Packaged under inert gas |
安全信息
| Storage Class Code【储存分类代码】 | 11 - Combustible Solids |
| WGK | WGK 3 |
